Search

Your search keyword '"Binder-Scholl, Gwendolyn"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Binder-Scholl, Gwendolyn" Remove constraint Author: "Binder-Scholl, Gwendolyn"
35 results on '"Binder-Scholl, Gwendolyn"'

Search Results

1. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

2. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

3. Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV

4. Supplement to: Genome Editing with Zinc Finger Nuclease Modified Autologous CD4 T-cells

5. Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV

6. Abstract 2562: Affinity-enhanced T-cell receptor (TCR) for adoptive T-cell therapy targeting MAGE-A4

8. Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286)

9. Abstract 2281: DNA methyl transferase inhibitors (DNMTis) upregulate NY-ESO expression in several human primary cells: implications for co-therapy with engineered adoptive T-cell therapies

10. Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.

11. Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR.

12. 192. Deep Phenotyping of Manufactured Enhanced-Affinity NY-ESO-1-Specific T Cells Reveals a Pattern of Effector and Memory Programming That Correlates with Clinical Outcome in Observed Cancer Indications

14. Preclinical safety testing of an affinity-optimised MAGE-A10 T cell receptor for adoptive T cell therapy

16. Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming

17. Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers.

18. 511. Enhanced-Affinity NY-ESO-1-Specific T Cells Exhibit Extended Functionality without Exhaustion in a Pattern of Effector and Memory Programming in Multiple Cancer Indications

19. Optimizing engineered TCR T cell therapy for synovial sarcoma

21. Gene Editing ofCCR5in Autologous CD4 T Cells of Persons Infected with HIV

22. Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses

23. Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT

24. Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

25. Abstract 4575: Correlates of clinical response following autologous stem cell transplant and adoptive immunotherapy with engineered T cells expressing an affinity-enhanced T cell receptor in patients with mutliple myeloma.

26. Efficient Clinical Scale Gene Modification via Zinc Finger Nuclease–Targeted Disruption of the HIV Co-receptor CCR5

27. Autologous aGVHD Associated with Infusion of T-Cells with Engineered Specificity for NY-ESO-1 and LAGE-1 Following High-Dose Melphalan and ASCT in Patients with Multiple Myeloma

28. Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT

29. Prolonged T Cell Persistence, Homing to Marrow and Selective Targeting of Antigen Positive Tumor in Multiple Myeloma Patients Following Adoptive Transfer of T Cells Genetically Engineered to Express an Affinity-Enhanced T Cell Receptor Against the Cancer Testis Antigens NY-ESO-1 and Lage-1

30. Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

31. Replication-Competent Retroviruses in Gene-Modified T Cells Used in Clinical Trials: Is It Time to Revise the Testing Requirements?

32. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016

33. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

35. T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.

Catalog

Books, media, physical & digital resources